Study wrapper · #135
Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.
Editor's note
This is a health-economic modeling study, not a clinical trial; it asks whether drugs are cost-effective for MASH with F2 to F3 fibrosis at U.S. prices, using a Markov model fed by a Bayesian network meta-analysis. Researchers reported both semaglutide (ICER ~$80,076/QALY) and tirzepatide (~$42,705/QALY) fell below the $100,000/QALY threshold, while resmetirom did not. The output is only as good as its inputs: efficacy estimates came from an indirect network comparison, drugs were each compared to standard of care rather than head-to-head, and drug price was the dominant driver in sensitivity analysis. The authors explicitly caution that tirzepatide is not FDA-approved for MASH and its estimate rests on a Phase 2 trial via network meta-analysis. Weight this as a pricing/value argument for payers, not as evidence of clinical efficacy in MASH; neither peptide's fibrosis benefit is established here, only modeled.
Plain-language abstract
This study used a computer model, not a new clinical trial, to ask whether three drugs give good value for money when used for MASH (a serious fatty-liver condition) with moderate scarring, at current U.S. prices. The model simulated patients over their lifetimes, using drug-effect estimates drawn from an indirect statistical comparison of existing trials. It measured value as cost per quality-adjusted life-year (QALY), with $100,000/QALY as the cutoff for good value. Tirzepatide came out most favorable ($42,705/QALY) and semaglutide was also within the threshold ($80,076/QALY), while resmetirom was well above it ($273,445/QALY). Drug price was the factor that mattered most. The authors warn that tirzepatide is not approved for MASH and its effect estimate comes from a single earlier-stage trial analyzed indirectly, so the tirzepatide result in particular should be read cautiously.